比较以阿扎那韦/利托那韦与洛匹那韦/利托那韦为基础方案的HIV感染者黏附分子与免疫参数评估
前瞻性随机24周研究纳入27例初治HIV感染者,CD4+ T细胞计数>250 cells/mm3,分别接受阿扎那韦/利托那韦(A组,15例)或洛匹那韦/利托那韦(B组,12例)为基础的抗逆转录病毒治疗,并观察随访至96周。96周时两组CD25+/CD8+ T细胞和血浆MCP-1/CCL-2升高而CD44+/CD8+ T细胞显著下降;HLA-DRII+/CD8+、CD44+/CD4+和CD11a+/CD4+在B组较A组显著升高。两组在基线及第24周的IMT、PWV和FMD均无差异。
要点
- 以蛋白酶抑制剂为基础的抗逆转录病毒治疗启动后,促动脉粥样硬化生物标志物在第24周下降、第96周回升。
- 洛匹那韦/利托那韦较阿扎那韦/利托那韦对HLA-DRII+/CD8+、CD44+/CD4+和CD11a+/CD4+的调节不利。
- 两组基线及第24周IMT、PWV和FMD均无差异。
核心结论
- 以蛋白酶抑制剂为基础方案启动抗逆转录病毒治疗使促动脉粥样硬化生物标志物在第24周下降、第96周回升;洛匹那韦/利托那韦较阿扎那韦/利托那韦对上述标志物产生不利调节。
研究设计与样本
- 前瞻性随机24周研究,纳入CD4+ T细胞计数>250 cells/mm3的初治HIV感染者,接受含阿扎那韦/利托那韦(A组)或洛匹那韦/利托那韦(B组)的方案,并观察随访至第96周。
- 共纳入27例,其中阿扎那韦/利托那韦组15例,洛匹那韦/利托那韦组12例。
- 在第0、4、12、24、48、72和96周评估CD4+与CD8+细胞上免疫激活和黏附分子表达及血浆细胞因子水平;第0和24周测量血流介导舒张(FMD)、脉搏波传导速度(PWV)和内膜中层厚度(IMT)。
主要发现
- 抗逆转录病毒治疗96周后,两组CD25+/CD8+ T细胞和血浆MCP-1/CCL-2浓度均升高,CD44+/CD8+ T细胞均显著下降。
- HLA-DRII+/CD8+、CD44+/CD4+和CD11a+/CD4+在组间存在差异,B组较A组显著升高。
- 两组基线及第24周的IMT、PWV和FMD均无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate changes in pro-atherosclerotic biomarkers and endothelial function in patients initiating two different PI-based regimens as part of ART. DESIGN: Prospective randomized 24 week study. Treatment-naive HIV-infected patients with CD4+ T cell count >250 cells/mm3 started PI-based regimens including atazanavir/ritonavir (Group A) or lopinavir/ritonavir (Group B) and were followed up in an observational follow-up study until week 96. METHODS: The expression of immune activation and adhesion molecules on CD4+ and CD8+ cells and plasma cytokine levels were assessed at weeks 0, 4, 12, 24, 48, 72 and 96. Flow-mediated dilation (FMD), pulse-wave velocity (PWV) and intima-media thickness (IMT) were measured at weeks 0 and 24. Median changes within (signed rank test) and between (Wilcoxon test) arms were calculated. RESULTS: Twenty-seven patients were enrolled, of whom 15 were treated with atazanavir/ritonavir and 12 with lopinavir/ritonavir. After 96 weeks of ART, CD25+/CD8+ T cells and plasma concentration of MCP-1/CCL-2 rose whereas CD44+/CD8+ T cells decreased significantly in both groups. Differences between treatments were noted for HLA-DRII+/CD8+, CD44+/CD4+ and CD11a+/CD4+, with significant increases in Group B versus Group A. No differences between groups regarding IMT, PWV and FMD were found at baseline and week 24. CONCLUSIONS: ART initiation with PI-based regimens led to a decrease in pro-atherosclerotic biomarkers at week 24, which then rebounded at week 96. Lopinavir/ritonavir treatment resulted in an unfavourable modulation of such markers compared with atazanavir/ritonavir treatment.
引用
- Squillace N, Trabattoni D, Muscatello A, et al. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. J Antimicrob Chemother. 2018. PMID: 29897513. doi:10.1093/jac/dky178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。